Mark Houston
Vanderbilt University School of Medicine, USA
Title: Efficacy and Safety of a Nutritional Supplement Combination on Dyslipidemia and Cardiovascular Inflammatory Markers
Biography
Biography: Mark Houston
Abstract
This study was a randomized, double-blind, placebo-controlled and single-center trial of 40 patients, consisting of a screening visit, a 2-week run-in, and a 4-month treatment period with a combination nutritional supplement (LC). Advanced lipid testing and advanced cardiovascular inflammatory markers were measured. LC® significantly reduced total cholesterol, LDL-C, VLDL-C, ox LDL, ApoB, TG, LDL-P, heart rate and diastolic blood pressure and increased HDL-P and increased LDL size compared to placebo at one month and four months. In addition, LC® significantly reduced hs-CRP, TNF alpha, IL-6 within the treatment group from baseline. There were no adverse effects in the treatment group. LC® did not lower Co enzyme Q 10 levels or adversely affect any other lab parameters that were measured. These changes would be expected to reduce cardiovascular risk. LC® is an effective and safe alternative to statins and other lipid- lowering drugs in the treatment of dyslipidemia.
